HC Wainwright Forecasts Strong Price Appreciation for Enlivex Therapeutics (NASDAQ:ENLV) Stock

Key Points

• HC Wainwright raised its price target on Enlivex from $13 to $20 and kept a "buy" rating, signaling expectations of strong price appreciation.
• Despite that bullish call, MarketBeat shows a consensus rating of "Hold" with a $16.50 consensus target, while the stock is trading near $0.87 (down ~8.2%) and well below analyst targets.
• Enlivex is a clinical‑stage biopharma developing Allocetra (reprogrammed apoptotic cell therapy) and has low institutional ownership (~1.02%), although several funds recently established or increased small stakes.

Enlivex Therapeutics (NASDAQ:ENLV - Get Free Report) had its price target raised by research analysts at HC Wainwright from $13.00 to $20.00 in a report released on Tuesday,Benzinga reports. The firm presently has a "buy" rating on the stock.

A number of other research firms have also recently commented on ENLV. Weiss Ratings restated a "sell (d-)" rating on shares of Enlivex Therapeutics in a report on Monday, December 29th. Wall Street Zen cut shares of Enlivex Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, March 28th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Enlivex Therapeutics has a consensus rating of "Hold" and a consensus price target of $16.50.

Enlivex Therapeutics Trading Down 8.2%

NASDAQ ENLV opened at $0.87 on Tuesday. The company's 50-day moving average price is $1.09 and its 200-day moving average price is $1.02. The stock has a market cap of $207.38 million, a PE ratio of -1.59 and a beta of 1.68. Enlivex Therapeutics has a 12 month low of $0.66 and a 12 month high of $2.10.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new position in Enlivex Therapeutics during the 4th quarter worth about $33,000. Invesco Ltd. bought a new position in Enlivex Therapeutics during the 4th quarter worth about $43,000. XTX Topco Ltd boosted its holdings in shares of Enlivex Therapeutics by 44.8% in the 4th quarter. XTX Topco Ltd now owns 61,800 shares of the company's stock valued at $43,000 after buying an additional 19,132 shares in the last quarter. Jane Street Group LLC boosted its holdings in shares of Enlivex Therapeutics by 244.1% in the 4th quarter. Jane Street Group LLC now owns 74,082 shares of the company's stock valued at $52,000 after buying an additional 52,553 shares in the last quarter. Finally, Susquehanna International Group LLP bought a new stake in shares of Enlivex Therapeutics in the 3rd quarter valued at about $57,000. 1.02% of the stock is currently owned by institutional investors.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company's lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.